) announced that ViiV Healthcare's Triumeq (a fixed-dose
combination of Tivicay, abacavir and lamivudine) has been cleared
by the FDA for the treatment of HIV-1 infection.
ViiV Healthcare is also looking to get the HIV drug approved in the
EU and has submitted a Marketing Authorisation Application to the
European Medicines Agency. The Committee for Medicinal Products for
Human Use has already rendered a positive opinion on the drug. The
drug will most likely gain EU approval in the third quarter of
We note that ViiV Healthcare, a company focused on the treatment of
HIV, was established by Glaxo and Pfizer (
) in 2009. After certain amendments in Oct 2012, Shionogi joined as
We are pleased with the approval of Triumeq in the U.S. The
single-pill regimen of Triumeq will reduce the pill-burden on
patients and improve convenience and compliance. It is also a step
forward for Tivicay, having been approved last year as an add-on
therapy to other antiretroviral agents.
ViiV Healthcare has been working on developing Tivicay-based
therapies. In Jun 2014, ViiV Healthcare entered into an agreement
with Janssen R&D Ireland Ltd., a subsidiary of Johnson &
), for the development and commercialization of a single tablet
combination of Tivicay and Johnson & Johnson's Edurant.
Glaxo is a Zacks Rank #5 (Strong Sell) stock. A better-ranked stock
in the health care sector is Allergan (
) carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
To read this article on Zacks.com click here.